Stocks · US
DVA
XNYS
DaVita Inc.
An overview for this page is not available in English yet. The figures below are updated daily.
Key figures 2026-10-06 basis
P/E13.45x
P/B—
P/S0.83x
EPS$13.28
ROE-110.77%
ROA4.79%
Dividend yield0.00%
EV/EBITDA8.71x
Debt/Equity-14.09
Free cash flow$1.6B
Returns and 52-week range
1W+2.97%
1M-1.95%
3M-21.81%
6M+20.51%
1Y+37.54%
YTD+57.54%
52W high$247.49
52W low$101.00
From 52W high-27.11%
Company
Peers in the same sector
| Company | Market cap | P/E | P/B | 1M |
|---|---|---|---|---|
| Madrigal Pharmaceuticals, Inc. Common Stock | $11.4B | — | 21.78 | -8.25% |
| Bio-Techne Corp. | $11.4B | 62.59 | 5.40 | +0.00% |
| BrightSpring Health Services, Inc. Common Stock | $12.3B | 33.52 | 5.99 | +4.97% |
| Elanco Animal Health Incorporated Common Stock | $11.2B | — | 1.71 | -8.24% |
| Halozyme Therapeutics, Inc. | $12.3B | 29.72 | 85.64 | -0.43% |
| BioMarin Pharmaceuticals Inc | $11.1B | 152.64 | 1.76 | -15.50% |
Sources and notes
This page summarizes public filings, market data and news for information only. It is not a recommendation to buy or sell any security. Figures are as of the dates shown; check the original filings before making decisions.